Company Filing History:
5 out of 242 
2 out of 270 
1 out of 1 
Years Active: 1994-2019
Title: Innovator Spotlight: Yiannis A Ioannou
Introduction:
Yiannis A Ioannou, a prolific inventor based in New York, NY, has made significant contributions to the field of biotechnology with his groundbreaking patents. With a total of 5 patents to his name, Yiannis A Ioannou continues to push the boundaries of innovation in cloning and expression technologies.
Latest Patents:
One of his latest patents involves the cloning and expression of biologically active .alpha.-galactosidase A. This innovative method focuses on producing large quantities of human .alpha.-Gal A by utilizing eukaryotic host cell expression systems. The recombinant .alpha.-Gal A produced through this process has diverse applications, including the treatment of Fabry Disease and the conversion of blood group antigens.
Another notable patent by Yiannis A Ioannou pertains to the cloning and expression of biologically active .alpha.-GalNAc. This invention targets the production of human .alpha.-GalNAc using eukaryotic host cell expression systems. The resulting .alpha.-GalNAc can be applied in the treatment of Schindler disease and the hydrolysis of .alpha.-N-acetylgalactosaminyl moieties in glycoconjugates.
Career Highlights:
Yiannis A Ioannou has made significant contributions to the biotechnology industry during his tenure at Mount Sinai School of Medicine of the City University of New York. His expertise in cloning and expression technologies has led to the development of cutting-edge solutions with real-world applications.
Collaborations:
Throughout his career, Yiannis A Ioannou has collaborated with esteemed professionals in the field, including Robert J Desnick and David F Bishop. These collaborations have played a crucial role in advancing his innovative research and bringing his inventions to fruition.
Conclusion:
Yiannis A Ioannou stands as a prominent figure in the biotechnology sector, with a track record of pioneering inventions that have the potential to revolutionize the field. His dedication to pushing the boundaries of innovation and collaboration with industry experts underscores his commitment to driving meaningful change through his groundbreaking work.